Fatemeh Khatami
University of Medical Sciences, Iran
Title: The impact of selective DNA methyltrasferase inhibitors on breast cancer: A systematic review
Biography
Biography: Fatemeh Khatami
Abstract
Epigenetic alterations mainly including methylation are post-transcriptional changes that are important in the way of triggering cell tumor genesis. The methylation is progressively documented as a suitable target for the advance cancer therapies because contrary to genetic changes there are reversible. In breast cancer some DNA methyltransferase inhibitors (DNMTi) has been checked through clinical trials. The present research provides a systematic review over the clinical trial studies in which the DNMTi were recruited for BC therapy alone or in combination with other chemotherapeutics or ionizing radiation. This systematic review run according to the latest version of PRISMA checklist guideline with Prospero code: CRD42017072567.
A total of thirteen studies recruited in which azacytidine, decitabin and green tea extract has been evaluated. A total of 7312 studies were retrieved which 4399 were duplicated ones. The 2913 remaining ones were earned from; Embase (441), ProQuest (137), Pubmed (1288), Scopus (694), and web of Science (352) central (1). Finally thirteen studies were included in the final analysis and there was high grade of concordance among reviewers (κ=0.9) in selecting the related studies which three of them were retrieved from other paper references. DNMTi can be used as a single agent therapy or in combination with other anticancer agents or treatment plans with high safety and efficacy.